Please login to the form below

Inlyta

This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.

Pfizer's 2021 revenue predictions soar to $82bn

In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased

Latest news

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

Outside the US, CDK4/6 inhibitor Ibrance was also up by 21%, while sales of tyrosine kinase inhibitor (TKI) Inlyta also increased by 29% globally following increased adoption in the US
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

indications. Sales for Pfizer tyrosine kinase inhibitor (TKI) Inlyta were also up by 34% operationally, following increased demand in the US and approvals in 2019 for a combination of the drug
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Both Opdivo combinations will compete with Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib), after the combination treatment received FDA approval in the same ... Topline results from the
BMS gains FDA approval for second Opdivo combo in kidney cancer

Armed with two Opdivo combinations in its arsenal, BMS is primed to take on Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (ipilimumab). ... Keytruda/Inlyta won an FDA approval in advanced RCC in
Pfizer, Sanofi and others set to increase US drug prices in 2021

drugs Ibrance (palbociclib) and Inlyta (axitinib).

More from news
Approximately 7 fully matching, plus 40 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in
Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

A stumble, but not a fall – what’s next for Opdivo?

Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
Oncology drugs under AMNOG

A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Grace Communications

We’re an independent healthcare brand communications agency with a host of awards that speak to our success. Combining razor-sharp insights...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story: ...
New Playbook Alert: Virtual Patient Engagement: ...
Millennials: the wellness generation: Looking at the results from a global healthcare research study focusing on the patients of the future...

Email:
Password:

Please login to the form below

Inlyta

Subscribe to our email news alerts

Quick links